Rearrangements of the lysine methyltransferase 2A (KMT2A) gene and mutations in nucleophosmin 1 (NPM1) are two of the most common genetic alterations seen in AML, occurring at rates of about 10% and 30%, respectively [98]. This evidence concerns the gene NPM1 and acute myeloid leukemia.